Antara (fenofibrate) Patient Case Study


Patient Case

For the treatment of primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia as adjunctive therapy to diet

Case study: the high-risk patient with mixed dyslipidemia1

A typical Antara patient has high LDL, low HDL, & high triglycerides, and requires fenofibrate adjunctive therapy to control lipid levels

ANTARA is a registered trademark of Lupin Limited.

At Diagnosis Post 3 months
(ANTARA added)
9 months
LDL 93 95 97
HDL 36 45 43
Triglycerides 212 137 140

This pre-diabetic patient was an ideal candidate for ANTARA, along with weight loss and low carb diet encouraged.

  1. Data on file. Lupin Pharmaceuticals, Inc.